Florida Senate - 2017                                     SB 424
       
       
        
       By Senator Rouson
       
       19-00569-17                                            2017424__
    1                        A bill to be entitled                      
    2         An act relating to controlled substances; amending s.
    3         893.03, F.S.; scheduling Mitragynine and 7
    4         Hydroxymitragynine, constituents of Kratom, in a
    5         schedule of controlled substances; scheduling isomers,
    6         esters, ethers, salts, and salts of isomers, esters,
    7         and ethers of Mitragynine and 7-Hydroxymitragynine in
    8         a schedule of controlled substances; providing an
    9         exception from scheduling for any drug product
   10         approved by the United States Food and Drug
   11         Administration which contains Mitragynine or 7
   12         Hydroxymitragynine; amending s. 893.13, F.S.;
   13         providing a criminal penalty; reenacting s.
   14         39.01(30)(a) and (g), F.S., relating to definitions
   15         used in ch. 39, F.S., s. 316.193(5), F.S., relating to
   16         driving under the influence, s. 322.2616(2)(c), F.S.,
   17         relating to suspension of driver licenses, s.
   18         327.35(5), F.S., relating to boating under the
   19         influence, s. 440.102(11)(b), F.S., relating to drug
   20         free workplace programs, ss. 458.3265(1)(e) and
   21         459.0137(1)(e), F.S., relating to pain-management
   22         clinics, s. 782.04(1)(a) and (4), F.S., relating to
   23         murder, s. 787.06(2)(a), F.S., relating to human
   24         trafficking, s. 817.563, F.S., relating to sale of
   25         substance in lieu of a controlled substance, s.
   26         831.31(1)(a) and (2), F.S., relating to counterfeit
   27         controlled substance, s. 856.015(1)(c), F.S., relating
   28         to open house parties, s. 893.02(4), F.S., relating to
   29         definitions used in ch. 893, F.S., ss. 893.035(2),
   30         (7)(a), and (8)(a) and 893.0356(2)(a) and (5), F.S.,
   31         relating to control of new substances, s.
   32         893.05(1)(d), F.S., relating to practitioners and
   33         persons administering controlled substances in their
   34         absence, s. 893.12(2)(b), (c), and (d), F.S., relating
   35         to contraband, seizure, forfeiture, and sale, s.
   36         893.13(1)(a), (c), (d), (e), (f), and (h), (2)(a),
   37         (4)(b), (5)(b), and (7)(a), F.S., relating to
   38         prohibited acts and penalties, and 921.0022(3)(b),
   39         (c), and (e), F.S., relating to the offense severity
   40         ranking chart of the Criminal Punishment Code, to
   41         incorporate the amendment made by the act to s.
   42         893.03, F.S., in references thereto; providing an
   43         effective date.
   44          
   45  Be It Enacted by the Legislature of the State of Florida:
   46  
   47         Section 1. Paragraph (c) of subsection (1) of section
   48  893.03, Florida Statutes, is amended to read:
   49         893.03 Standards and schedules.—The substances enumerated
   50  in this section are controlled by this chapter. The controlled
   51  substances listed or to be listed in Schedules I, II, III, IV,
   52  and V are included by whatever official, common, usual,
   53  chemical, trade name, or class designated. The provisions of
   54  this section shall not be construed to include within any of the
   55  schedules contained in this section any excluded drugs listed
   56  within the purview of 21 C.F.R. s. 1308.22, styled “Excluded
   57  Substances”; 21 C.F.R. s. 1308.24, styled “Exempt Chemical
   58  Preparations”; 21 C.F.R. s. 1308.32, styled “Exempted
   59  Prescription Products”; or 21 C.F.R. s. 1308.34, styled “Exempt
   60  Anabolic Steroid Products.”
   61         (1) SCHEDULE I.—A substance in Schedule I has a high
   62  potential for abuse and has no currently accepted medical use in
   63  treatment in the United States and in its use under medical
   64  supervision does not meet accepted safety standards. The
   65  following substances are controlled in Schedule I:
   66         (c) Unless specifically excepted or unless listed in
   67  another schedule, any material, compound, mixture, or
   68  preparation that contains any quantity of the following
   69  hallucinogenic substances or that contains any of their salts,
   70  isomers, including optical, positional, or geometric isomers,
   71  homologues, nitrogen-heterocyclic analogs, esters, ethers, and
   72  salts of isomers, homologues, nitrogen-heterocyclic analogs,
   73  esters, or ethers, if the existence of such salts, isomers, and
   74  salts of isomers is possible within the specific chemical
   75  designation or class description:
   76         1. Alpha-Ethyltryptamine.
   77         2. 4-Methylaminorex (2-Amino-4-methyl-5-phenyl-2
   78  oxazoline).
   79         3. Aminorex (2-Amino-5-phenyl-2-oxazoline).
   80         4. DOB (4-Bromo-2,5-dimethoxyamphetamine).
   81         5. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
   82         6. Bufotenine.
   83         7. Cannabis.
   84         8. Cathinone.
   85         9. DET (Diethyltryptamine).
   86         10. 2,5-Dimethoxyamphetamine.
   87         11. DOET (4-Ethyl-2,5-Dimethoxyamphetamine).
   88         12. DMT (Dimethyltryptamine).
   89         13. PCE (N-Ethyl-1-phenylcyclohexylamine)(Ethylamine analog
   90  of phencyclidine).
   91         14. JB-318 (N-Ethyl-3-piperidyl benzilate).
   92         15. N-Ethylamphetamine.
   93         16. Fenethylline.
   94         17. 3,4-Methylenedioxy-N-hydroxyamphetamine.
   95         18. Ibogaine.
   96         19. LSD (Lysergic acid diethylamide).
   97         20. Mescaline.
   98         21. Methcathinone.
   99         22. 5-Methoxy-3,4-methylenedioxyamphetamine.
  100         23. PMA (4-Methoxyamphetamine).
  101         24. PMMA (4-Methoxymethamphetamine).
  102         25. DOM (4-Methyl-2,5-dimethoxyamphetamine).
  103         26. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
  104         27. MDA (3,4-Methylenedioxyamphetamine).
  105         28. JB-336 (N-Methyl-3-piperidyl benzilate).
  106         29. N,N-Dimethylamphetamine.
  107         30. Parahexyl.
  108         31. Peyote.
  109         32. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine
  110  analog of phencyclidine).
  111         33. Psilocybin.
  112         34. Psilocyn.
  113         35. Salvia divinorum, except for any drug product approved
  114  by the United States Food and Drug Administration which contains
  115  Salvia divinorum or its isomers, esters, ethers, salts, and
  116  salts of isomers, esters, and ethers, if the existence of such
  117  isomers, esters, ethers, and salts is possible within the
  118  specific chemical designation.
  119         36. Salvinorin A, except for any drug product approved by
  120  the United States Food and Drug Administration which contains
  121  Salvinorin A or its isomers, esters, ethers, salts, and salts of
  122  isomers, esters, and ethers, if the existence of such isomers,
  123  esters, ethers, and salts is possible within the specific
  124  chemical designation.
  125         37. Xylazine.
  126         38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)
  127  (Thiophene analog of phencyclidine).
  128         39. 3,4,5-Trimethoxyamphetamine.
  129         40. Methylone (3,4-Methylenedioxymethcathinone).
  130         41. MDPV (3,4-Methylenedioxypyrovalerone).
  131         42. Methylmethcathinone.
  132         43. Methoxymethcathinone.
  133         44. Fluoromethcathinone.
  134         45. Methylethcathinone.
  135         46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
  136  yl)phenol) and its dimethyloctyl (C8) homologue.
  137         47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2
  138  methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].
  139         48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
  140         49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
  141         50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
  142  naphthoyl)indole).
  143         51. BZP (Benzylpiperazine).
  144         52. Fluorophenylpiperazine.
  145         53. Methylphenylpiperazine.
  146         54. Chlorophenylpiperazine.
  147         55. Methoxyphenylpiperazine.
  148         56. DBZP (1,4-Dibenzylpiperazine).
  149         57. TFMPP (Trifluoromethylphenylpiperazine).
  150         58. MBDB (Methylbenzodioxolylbutanamine) or (3,4
  151  Methylenedioxy-N-methylbutanamine).
  152         59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
  153         60. 5-Hydroxy-N-methyltryptamine.
  154         61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
  155         62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
  156         63. Methyltryptamine.
  157         64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
  158         65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
  159         66. Tyramine (4-Hydroxyphenethylamine).
  160         67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
  161         68. DiPT (N,N-Diisopropyltryptamine).
  162         69. DPT (N,N-Dipropyltryptamine).
  163         70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
  164         71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
  165         72. DOI (4-Iodo-2,5-dimethoxyamphetamine).
  166         73. DOC (4-Chloro-2,5-dimethoxyamphetamine).
  167         74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
  168         75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
  169         76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
  170         77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
  171         78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
  172         79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
  173         80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
  174         81. Butylone (3,4-Methylenedioxy-alpha
  175  methylaminobutyrophenone).
  176         82. Ethcathinone.
  177         83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
  178         84. Naphyrone (Naphthylpyrovalerone).
  179         85. Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone).
  180         86. 3,4-Methylenedioxy-N,N-diethylcathinone.
  181         87. 3,4-Methylenedioxy-propiophenone.
  182         88. 3,4-Methylenedioxy-alpha-bromopropiophenone.
  183         89. 3,4-Methylenedioxy-propiophenone-2-oxime.
  184         90. 3,4-Methylenedioxy-N-acetylcathinone.
  185         91. 3,4-Methylenedioxy-N-acetylmethcathinone.
  186         92. 3,4-Methylenedioxy-N-acetylethcathinone.
  187         93. Bromomethcathinone.
  188         94. Buphedrone (alpha-Methylamino-butyrophenone).
  189         95. Eutylone (3,4-Methylenedioxy-alpha
  190  ethylaminobutyrophenone).
  191         96. Dimethylcathinone.
  192         97. Dimethylmethcathinone.
  193         98. Pentylone (3,4-Methylenedioxy-alpha
  194  methylaminovalerophenone).
  195         99. MDPPP (3,4-Methylenedioxy-alpha
  196  pyrrolidinopropiophenone).
  197         100. MDPBP (3,4-Methylenedioxy-alpha
  198  pyrrolidinobutyrophenone).
  199         101. MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
  200         102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
  201         103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
  202  (Benocyclidine).
  203         104. F-MABP (Fluoromethylaminobutyrophenone).
  204         105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
  205         106. Et-PBP (Ethylpyrrolidinobutyrophenone).
  206         107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
  207         108. Me-EABP (Methylethylaminobutyrophenone).
  208         109. Etizolam.
  209         110. PPP (Pyrrolidinopropiophenone).
  210         111. PBP (Pyrrolidinobutyrophenone).
  211         112. PVP (Pyrrolidinovalerophenone) or
  212  (Pyrrolidinopentiophenone).
  213         113. MPPP (Methyl-alpha-pyrrolidinopropiophenone).
  214         114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
  215         115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
  216         116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
  217         117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
  218         118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
  219         119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
  220         120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
  221         121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
  222  2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
  223         122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
  224         123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
  225         124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
  226         125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
  227         126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
  228         127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
  229         128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
  230         129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
  231         130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
  232  (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
  233  ol).
  234         131. HU-308 ([(1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-methyloctan
  235  2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]
  236  methanol).
  237         132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1
  238  methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene
  239  1,4-dione).
  240         133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene).
  241         134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)
  242  undecanamide).
  243         135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)
  244  undecanamide).
  245         136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2
  246  methyloctan-2-yl)phenol).
  247         137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
  248         138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole).
  249         139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
  250         140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2
  251  methoxyphenylacetyl)indole).
  252         141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4
  253  morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
  254  naphthalenylmethanone).
  255         142. WIN55,212-3 ([(3S)-2,3-Dihydro-5-methyl-3-(4
  256  morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1
  257  naphthalenylmethanone).
  258         143. Pentedrone (alpha-Methylaminovalerophenone).
  259         144. Fluoroamphetamine.
  260         145. Fluoromethamphetamine.
  261         146. Methoxetamine.
  262         147. Methiopropamine.
  263         148. Methylbuphedrone (Methyl-alpha
  264  methylaminobutyrophenone).
  265         149. APB ((2-Aminopropyl)benzofuran).
  266         150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran).
  267         151. UR-144 (1-Pentyl-3-(2,2,3,3
  268  tetramethylcyclopropanoyl)indole).
  269         152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
  270  tetramethylcyclopropanoyl)indole).
  271         153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
  272  tetramethylcyclopropanoyl)indole).
  273         154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
  274         155. AM-2233(1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
  275  iodobenzoyl)indole).
  276         156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
  277  carboxamide).
  278         157. URB-597 ((3′-(Aminocarbonyl)[1,1′-biphenyl]-3-yl)
  279  cyclohexylcarbamate).
  280         158. URB-602 ([1,1′-Biphenyl]-3-yl-carbamic acid,
  281  cyclohexyl ester).
  282         159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1
  283  benzoxazin-4-one).
  284         160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
  285         161. 2C-H (2,5-Dimethoxyphenethylamine).
  286         162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
  287         163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
  288         164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
  289  methoxybenzyl)]phenethylamine).
  290         165. MDMA (3,4-Methylenedioxymethamphetamine).
  291         166. PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
  292         167. Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
  293  carboxylate).
  294         168. BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
  295  carboxylate).
  296         169. Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
  297  3-carboxamide).
  298         170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
  299  pentylindazole-3-carboxamide).
  300         171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
  301  (4-fluorobenzyl)indazole-3-carboxamide).
  302         172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
  303  1-pentylindazole-3-carboxamide).
  304         173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
  305  yl)-1-(fluoropentyl)indole-3-carboxamide).
  306         174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
  307  methoxybenzyl)]phenethylamine).
  308         175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
  309  methoxybenzyl)]phenethylamine).
  310         176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
  311  (cyclohexylmethyl)indazole-3-carboxamide).
  312         177. FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
  313  carboxylate).
  314         178. Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
  315  3-carboxamide).
  316         179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
  317  (fluoropentyl)indazole-3-carboxamide).
  318         180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole).
  319         181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl
  320  1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).
  321         182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9
  322  (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
  323  hexahydrobenzo[c]chromen-1-ol).
  324         183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9
  325  (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a
  326  hexahydrobenzo[c]chromen-1-ol).
  327         184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)
  328  6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9
  329  diol).
  330         185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6
  331  dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a
  332  tetrahydro-6aH-benzo[c]chromen-1-ol).
  333         186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl
  334  6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).
  335         187. MAPB ((2-Methylaminopropyl)benzofuran).
  336         188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).
  337         189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).
  338         190. Synthetic Cannabinoids.—Unless specifically excepted
  339  or unless listed in another schedule or contained within a
  340  pharmaceutical product approved by the United States Food and
  341  Drug Administration, any material, compound, mixture, or
  342  preparation that contains any quantity of a synthetic
  343  cannabinoid found to be in any of the following chemical class
  344  descriptions, or homologues, nitrogen-heterocyclic analogs,
  345  isomers (including optical, positional, or geometric), esters,
  346  ethers, salts, and salts of homologues, nitrogen-heterocyclic
  347  analogs, isomers, esters, or ethers, whenever the existence of
  348  such homologues, nitrogen-heterocyclic analogs, isomers, esters,
  349  ethers, salts, and salts of isomers, esters, or ethers is
  350  possible within the specific chemical class or designation.
  351  Since nomenclature of these synthetically produced cannabinoids
  352  is not internationally standardized and may continually evolve,
  353  these structures or the compounds of these structures shall be
  354  included under this subparagraph, regardless of their specific
  355  numerical designation of atomic positions covered, if it can be
  356  determined through a recognized method of scientific testing or
  357  analysis that the substance contains properties that fit within
  358  one or more of the following categories:
  359         a. Tetrahydrocannabinols.—Any tetrahydrocannabinols
  360  naturally contained in a plant of the genus Cannabis, the
  361  synthetic equivalents of the substances contained in the plant
  362  or in the resinous extracts of the genus Cannabis, or synthetic
  363  substances, derivatives, and their isomers with similar chemical
  364  structure and pharmacological activity, including, but not
  365  limited to, Delta 9 tetrahydrocannabinols and their optical
  366  isomers, Delta 8 tetrahydrocannabinols and their optical
  367  isomers, Delta 6a,10a tetrahydrocannabinols and their optical
  368  isomers, or any compound containing a tetrahydrobenzo[c]chromene
  369  structure with substitution at either or both the 3-position or
  370  9-position, with or without substitution at the 1-position with
  371  hydroxyl or alkoxy groups, including, but not limited to:
  372         (I) Tetrahydrocannabinol.
  373         (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
  374  (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
  375  ol).
  376         (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3
  377  (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1
  378  ol).
  379         (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3
  380  (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
  381         (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan
  382  2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
  383         (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan
  384  2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
  385         (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-(2,3
  386  dimethylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).
  387         (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)
  388  6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
  389         (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl
  390  6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
  391         (X) Parahexyl.
  392         b. Naphthoylindoles, Naphthoylindazoles,
  393  Naphthoylcarbazoles, Naphthylmethylindoles,
  394  Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any
  395  compound containing a naphthoylindole, naphthoylindazole,
  396  naphthoylcarbazole, naphthylmethylindole,
  397  naphthylmethylindazole, or naphthylmethylcarbazole structure,
  398  with or without substitution on the indole, indazole, or
  399  carbazole ring to any extent, whether or not substituted on the
  400  naphthyl ring to any extent, including, but not limited to:
  401         (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
  402         (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1
  403  naphthoyl)indole).
  404         (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
  405         (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).
  406         (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
  407         (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
  408         (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
  409         (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).
  410         (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).
  411         (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
  412         (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
  413         (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).
  414         (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
  415         (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1
  416  naphthoyl)indole).
  417         (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole).
  418         (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
  419         (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1
  420  naphthoyl)indole).
  421         (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-naphthoyl)indole).
  422         (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
  423         (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl)indole).
  424         (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl)indole).
  425         (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1
  426  naphthylmethyl]indole).
  427         (XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1
  428  naphthoyl)indole).
  429         (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1
  430  naphthoyl)indole).
  431         (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1
  432  naphthoyl)indole).
  433         (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
  434         (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole).
  435         (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
  436         (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole).
  437         (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole).
  438         (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1
  439  naphthoyl)indole).
  440         (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1
  441  naphthoyl)indole).
  442         (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1
  443  naphthoyl)indole).
  444         (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1
  445  naphthoyl)indole).
  446         (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1
  447  naphthoyl)indole).
  448         (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl)indole).
  449         (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1
  450  naphthoyl)indazole).
  451         (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1
  452  naphthoyl)indole).
  453         (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1
  454  naphthoyl)indole).
  455         (XL) EG-018 (9-Pentyl-3-(1-naphthoyl)carbazole).
  456         (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1
  457  naphthoyl)carbazole).
  458         c. Naphthoylpyrroles.—Any compound containing a
  459  naphthoylpyrrole structure, with or without substitution on the
  460  pyrrole ring to any extent, whether or not substituted on the
  461  naphthyl ring to any extent, including, but not limited to:
  462         (I) JWH-030 (1-Pentyl-3-(1-naphthoyl)pyrrole).
  463         (II) JWH-031 (1-Hexyl-3-(1-naphthoyl)pyrrole).
  464         (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl)pyrrole).
  465         (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl)pyrrole).
  466         (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl)pyrrole).
  467         (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1
  468  naphthoyl)pyrrole).
  469         (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1
  470  naphthoyl)pyrrole).
  471         (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1
  472  naphthoyl)pyrrole).
  473         (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1
  474  naphthoyl)pyrrole).
  475         (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1
  476  naphthoyl)pyrrole).
  477         d. Naphthylmethylenindenes.—Any compound containing a
  478  naphthylmethylenindene structure, with or without substitution
  479  at the 3-position of the indene ring to any extent, whether or
  480  not substituted on the naphthyl ring to any extent, including,
  481  but not limited to, JWH-176 (3-Pentyl-1
  482  (naphthylmethylene)indene).
  483         e. Phenylacetylindoles and Phenylacetylindazoles.—Any
  484  compound containing a phenylacetylindole or phenylacetylindazole
  485  structure, with or without substitution on the indole or
  486  indazole ring to any extent, whether or not substituted on the
  487  phenyl ring to any extent, including, but not limited to:
  488         (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).
  489         (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).
  490         (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).
  491         (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).
  492         (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).
  493         (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).
  494         (VII) Cannabipiperidiethanone.
  495         (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2
  496  methoxyphenylacetyl)indole).
  497         f. Cyclohexylphenols.—Any compound containing a
  498  cyclohexylphenol structure, with or without substitution at the
  499  5-position of the phenolic ring to any extent, whether or not
  500  substituted on the cyclohexyl ring to any extent, including, but
  501  not limited to:
  502         (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2
  503  yl)phenol).
  504         (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)
  505  homologue).
  506         (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2
  507  methyloctan-2-yl)phenol).
  508         g. Benzoylindoles and Benzoylindazoles.—Any compound
  509  containing a benzoylindole or benzoylindazole structure, with or
  510  without substitution on the indole or indazole ring to any
  511  extent, whether or not substituted on the phenyl ring to any
  512  extent, including, but not limited to:
  513         (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).
  514         (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).
  515         (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
  516  iodo-5-nitrobenzoyl)indole).
  517         (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-(4
  518  methoxybenzoyl)indole).
  519         (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2
  520  iodobenzoyl)indole).
  521         (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).
  522         (VII) RCS-4 C4 homologue (1-Butyl-3-(4
  523  methoxybenzoyl)indole).
  524         (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo
  525  3-(4-methoxybenzoyl)indole).
  526         h. Tetramethylcyclopropanoylindoles and
  527  Tetramethylcyclopropanoylindazoles.—Any compound containing a
  528  tetramethylcyclopropanoylindole or
  529  tetramethylcyclopropanoylindazole structure, with or without
  530  substitution on the indole or indazole ring to any extent,
  531  whether or not substituted on the tetramethylcyclopropyl group
  532  to any extent, including, but not limited to:
  533         (I) UR-144 (1-Pentyl-3-(2,2,3,3
  534  tetramethylcyclopropanoyl)indole).
  535         (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3
  536  tetramethylcyclopropanoyl)indole).
  537         (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3
  538  tetramethylcyclopropanoyl)indole).
  539         (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3
  540  tetramethylcyclopropanoyl)indole).
  541         (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3
  542  tetramethylcyclopropanoyl)indole).
  543         (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3
  544  tetramethylcyclopropanoyl)indole).
  545         (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3
  546  tetramethylcyclopropanoyl)indole).
  547         (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3
  548  tetramethylcyclopropanoyl)indazole).
  549         (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3
  550  tetramethylcyclopropanoyl)indole).
  551         (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3
  552  tetramethylcyclopropanoyl)indole).
  553         i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole
  554  carboxamides, and Adamantylindazole carboxamides.—Any compound
  555  containing an adamantoyl indole, adamantoyl indazole, adamantyl
  556  indole carboxamide, or adamantyl indazole carboxamide structure,
  557  with or without substitution on the indole or indazole ring to
  558  any extent, whether or not substituted on the adamantyl ring to
  559  any extent, including, but not limited to:
  560         (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
  561         (II) Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole
  562  3-carboxamide).
  563         (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3
  564  carboxamide).
  565         (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1
  566  adamantoyl)indole).
  567         (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).
  568         (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).
  569         (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1
  570  adamantoyl)indole).
  571         j. Quinolinylindolecarboxylates,
  572  Quinolinylindazolecarboxylates, Quinolinylindolecarboxamides,
  573  and Quinolinylindazolecarboxamides.—Any compound containing a
  574  quinolinylindole carboxylate, quinolinylindazole carboxylate,
  575  isoquinolinylindole carboxylate, isoquinolinylindazole
  576  carboxylate, quinolinylindole carboxamide, quinolinylindazole
  577  carboxamide, isoquinolinylindole carboxamide, or
  578  isoquinolinylindazole carboxamide structure, with or without
  579  substitution on the indole or indazole ring to any extent,
  580  whether or not substituted on the quinoline or isoquinoline ring
  581  to any extent, including, but not limited to:
  582         (I) PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
  583         (II) Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3
  584  carboxylate).
  585         (III) BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3
  586  carboxylate).
  587         (IV) FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3
  588  carboxylate).
  589         (V) NPB-22 (8-Quinolinyl 1-pentylindazole-3-carboxylate).
  590         (VI) Fluoro NPB-22 (8-Quinolinyl 1-(fluoropentyl)indazole
  591  3-carboxylate).
  592         (VII) FUB-NPB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indazole
  593  3-carboxylate).
  594         (VIII) THJ (8-Quinolinyl 1-pentylindazole-3-carboxamide).
  595         (IX) Fluoro THJ (8-Quinolinyl 1-(fluoropentyl)indazole-3
  596  carboxamide).
  597         k. Naphthylindolecarboxylates and
  598  Naphthylindazolecarboxylates.—Any compound containing a
  599  naphthylindole carboxylate or naphthylindazole carboxylate
  600  structure, with or without substitution on the indole or
  601  indazole ring to any extent, whether or not substituted on the
  602  naphthyl ring to any extent, including, but not limited to:
  603         (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3
  604  carboxylate).
  605         (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3
  606  carboxylate).
  607         (III) Fluoro SDB-005 (1-Naphthalenyl 1
  608  (fluoropentyl)indazole-3-carboxylate).
  609         (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3
  610  carboxylate).
  611         (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3
  612  carboxylate).
  613         l. Naphthylindole carboxamides and Naphthylindazole
  614  carboxamides.—Any compound containing a naphthylindole
  615  carboxamide or naphthylindazole carboxamide structure, with or
  616  without substitution on the indole or indazole ring to any
  617  extent, whether or not substituted on the naphthyl ring to any
  618  extent, including, but not limited to:
  619         (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).
  620         (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole
  621  3-carboxamide).
  622         (III) Chloro-NNEI (N-Naphthalen-1-yl 1
  623  (chloropentyl)indole-3-carboxamide).
  624         (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3
  625  carboxamide).
  626         (V) Fluoro MN-18 (N-Naphthalen-1-yl 1
  627  (fluoropentyl)indazole-3-carboxamide).
  628         m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl
  629  indazole carboxamides, Alkylcarbonyl indole carboxylates, and
  630  Alkylcarbonyl indazole carboxylates.—Any compound containing an
  631  alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,
  632  1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3
  633  phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an
  634  indole carboxamide, indazole carboxamide, indole carboxylate, or
  635  indazole carboxylate, with or without substitution on the indole
  636  or indazole ring to any extent, whether or not substituted on
  637  the alkylcarbonyl group to any extent, including, but not
  638  limited to:
  639         (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1
  640  pentylindole-3-carboxamide).
  641         (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
  642  yl)-1-(fluoropentyl)indole-3-carboxamide).
  643         (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
  644  (fluoropentyl)indole-3-carboxamide).
  645         (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
  646  pentylindazole-3-carboxamide).
  647         (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)
  648  1-(fluoropentyl)indazole-3-carboxamide).
  649         (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)
  650  1-pentylindazole-3-carboxamide).
  651         (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1
  652  oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).
  653         (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
  654  (4-fluorobenzyl)indazole-3-carboxamide).
  655         (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
  656  yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
  657         (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1
  658  (cyclohexylmethyl)indazole-3-carboxamide).
  659         (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
  660  (cyclohexylmethyl)indazole-3-carboxamide).
  661         (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2
  662  yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
  663         (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
  664  pentylindazole-3-carboxamide).
  665         (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1
  666  (fluoropentyl)indazole-3-carboxamide).
  667         (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4
  668  fluorobenzyl)indazole-3-carboxamide).
  669         (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
  670  2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
  671         (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
  672  2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
  673         (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
  674  2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).
  675         (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
  676  fluoropentyl)indole-3-carboxamide).
  677         (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5
  678  fluoropentyl)indazole-3-carboxamide).
  679         (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1
  680  (cyclohexylmethyl)indazole-3-carboxamide).
  681         (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4
  682  fluorobenzyl)indazole-3-carboxamide).
  683         (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan
  684  2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).
  685         n. Cumylindolecarboxamides and Cumylindazolecarboxamides.
  686  Any compound containing a N-(2-phenylpropan-2-yl) indole
  687  carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide
  688  structure, with or without substitution on the indole or
  689  indazole ring to any extent, whether or not substituted on the
  690  phenyl ring of the cumyl group to any extent, including, but not
  691  limited to:
  692         (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3
  693  carboxamide).
  694         (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1
  695  (fluoropentyl)indole-3-carboxamide).
  696         o. Other Synthetic Cannabinoids.—Any material, compound,
  697  mixture, or preparation that contains any quantity of a
  698  Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:
  699         (I) With or without modification or replacement of a
  700  carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage
  701  between either two core rings, or linkage between a core ring
  702  and group structure, with or without the addition of a carbon or
  703  replacement of a carbon;
  704         (II) With or without replacement of a core ring or group
  705  structure, whether or not substituted on the ring or group
  706  structures to any extent; and
  707         (III) Is a cannabinoid receptor agonist, unless
  708  specifically excepted or unless listed in another schedule or
  709  contained within a pharmaceutical product approved by the United
  710  States Food and Drug Administration.
  711         191. Substituted Cathinones.—Unless specifically excepted,
  712  listed in another schedule, or contained within a pharmaceutical
  713  product approved by the United States Food and Drug
  714  Administration, any material, compound, mixture, or preparation,
  715  including its salts, isomers, esters, or ethers, and salts of
  716  isomers, esters, or ethers, whenever the existence of such salts
  717  is possible within any of the following specific chemical
  718  designations:
  719         a. Any compound containing a 2-amino-1-phenyl-1-propanone
  720  structure;
  721         b. Any compound containing a 2-amino-1-naphthyl-1-propanone
  722  structure; or
  723         c. Any compound containing a 2-amino-1-thiophenyl-1
  724  propanone structure,
  725  whether or not the compound is further modified:
  726         (I) With or without substitution on the ring system to any
  727  extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,
  728  haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused
  729  dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide
  730  substituents;
  731         (II) With or without substitution at the 3-propanone
  732  position with an alkyl substituent or removal of the methyl
  733  group at the 3-propanone position;
  734         (III) With or without substitution at the 2-amino nitrogen
  735  atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or
  736  not further substituted in the ring system; or
  737         (IV) With or without inclusion of the 2-amino nitrogen atom
  738  in a cyclic structure, including, but not limited to:
  739         (A) Methcathinone.
  740         (B) Ethcathinone.
  741         (C) Methylone (3,4-Methylenedioxymethcathinone).
  742         (D) 2,3-Methylenedioxymethcathinone.
  743         (E) MDPV (3,4-Methylenedioxypyrovalerone).
  744         (F) Methylmethcathinone.
  745         (G) Methoxymethcathinone.
  746         (H) Fluoromethcathinone.
  747         (I) Methylethcathinone.
  748         (J) Butylone (3,4-Methylenedioxy-alpha
  749  methylaminobutyrophenone).
  750         (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
  751         (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).
  752         (M) Naphyrone (Naphthylpyrovalerone).
  753         (N) Bromomethcathinone.
  754         (O) Buphedrone (alpha-Methylaminobutyrophenone).
  755         (P) Eutylone (3,4-Methylenedioxy-alpha
  756  ethylaminobutyrophenone).
  757         (Q) Dimethylcathinone.
  758         (R) Dimethylmethcathinone.
  759         (S) Pentylone (3,4-Methylenedioxy-alpha
  760  methylaminovalerophenone).
  761         (T) Pentedrone (alpha-Methylaminovalerophenone).
  762         (U) MDPPP (3,4-Methylenedioxy-alpha
  763  pyrrolidinopropiophenone).
  764         (V) MDPBP (3,4-Methylenedioxy-alpha
  765  pyrrolidinobutyrophenone).
  766         (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone).
  767         (X) PPP (Pyrrolidinopropiophenone).
  768         (Y) PVP (Pyrrolidinovalerophenone) or
  769  (Pyrrolidinopentiophenone).
  770         (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
  771         (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone).
  772         (BB) F-MABP (Fluoromethylaminobutyrophenone).
  773         (CC) Me-EABP (Methylethylaminobutyrophenone).
  774         (DD) PBP (Pyrrolidinobutyrophenone).
  775         (EE) MeO-PBP (Methoxypyrrolidinobutyrophenone).
  776         (FF) Et-PBP (Ethylpyrrolidinobutyrophenone).
  777         (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
  778         (HH) Dimethylone (3,4-Methylenedioxy-N,N
  779  dimethylcathinone).
  780         (II) 3,4-Methylenedioxy-N,N-diethylcathinone.
  781         (JJ) 3,4-Methylenedioxy-N-acetylcathinone.
  782         (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.
  783         (LL) 3,4-Methylenedioxy-N-acetylethcathinone.
  784         (MM) Methylbuphedrone (Methyl-alpha
  785  methylaminobutyrophenone).
  786         (NN) Methyl-alpha-methylaminohexanophenone.
  787         (OO) N-Ethyl-N-methylcathinone.
  788         (PP) PHP (Pyrrolidinohexanophenone).
  789         (QQ) PV8 (Pyrrolidinoheptanophenone).
  790         (RR) Chloromethcathinone.
  791         (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.
  792         192. Substituted Phenethylamines.—Unless specifically
  793  excepted or unless listed in another schedule, or contained
  794  within a pharmaceutical product approved by the United States
  795  Food and Drug Administration, any material, compound, mixture,
  796  or preparation, including its salts, isomers, esters, or ethers,
  797  and salts of isomers, esters, or ethers, whenever the existence
  798  of such salts is possible within any of the following specific
  799  chemical designations, any compound containing a phenethylamine
  800  structure, without a beta-keto group, and without a benzyl group
  801  attached to the amine group, whether or not the compound is
  802  further modified with or without substitution on the phenyl ring
  803  to any extent with alkyl, alkylthio, nitro, alkoxy, thio,
  804  halide, fused alkylenedioxy, fused furan, fused benzofuran,
  805  fused dihydrofuran, or fused tetrahydropyran substituents,
  806  whether or not further substituted on a ring to any extent, with
  807  or without substitution at the alpha or beta position by any
  808  alkyl substituent, with or without substitution at the nitrogen
  809  atom, and with or without inclusion of the 2-amino nitrogen atom
  810  in a cyclic structure, including, but not limited to:
  811         a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
  812         b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
  813         c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
  814         d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
  815         e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
  816         f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
  817         g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
  818         h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
  819         i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
  820         j. 2C-H (2,5-Dimethoxyphenethylamine).
  821         k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
  822         l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
  823         m. MDMA (3,4-Methylenedioxymethamphetamine).
  824         n. MBDB (Methylbenzodioxolylbutanamine) or (3,4
  825  Methylenedioxy-N-methylbutanamine).
  826         o. MDA (3,4-Methylenedioxyamphetamine).
  827         p. 2,5-Dimethoxyamphetamine.
  828         q. Fluoroamphetamine.
  829         r. Fluoromethamphetamine.
  830         s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine).
  831         t. DOB (4-Bromo-2,5-dimethoxyamphetamine).
  832         u. DOC (4-Chloro-2,5-dimethoxyamphetamine).
  833         v. DOET (4-Ethyl-2,5-dimethoxyamphetamine).
  834         w. DOI (4-Iodo-2,5-dimethoxyamphetamine).
  835         x. DOM (4-Methyl-2,5-dimethoxyamphetamine).
  836         y. PMA (4-Methoxyamphetamine).
  837         z. N-Ethylamphetamine.
  838         aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.
  839         bb. 5-Methoxy-3,4-methylenedioxyamphetamine.
  840         cc. PMMA (4-Methoxymethamphetamine).
  841         dd. N,N-Dimethylamphetamine.
  842         ee. 3,4,5-Trimethoxyamphetamine.
  843         ff. 4-APB (4-(2-Aminopropyl)benzofuran).
  844         gg. 5-APB (5-(2-Aminopropyl)benzofuran).
  845         hh. 6-APB (6-(2-Aminopropyl)benzofuran).
  846         ii. 7-APB (7-(2-Aminopropyl)benzofuran).
  847         jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran).
  848         kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran).
  849         ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran).
  850         mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
  851         nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).
  852         oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).
  853         pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).
  854         qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).
  855         rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).
  856         ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3
  857  dihydrobenzofuran),
  858  
  859  which does not include phenethylamine, mescaline as described in
  860  subparagraph 20., substituted cathinones as described in
  861  subparagraph 191., N-Benzyl phenethylamine compounds as
  862  described in subparagraph 193., or methamphetamine as described
  863  in subparagraph (2)(c)4.
  864         193. N-Benzyl Phenethylamine Compounds.—Unless specifically
  865  excepted or unless listed in another schedule, or contained
  866  within a pharmaceutical product approved by the United States
  867  Food and Drug Administration, any material, compound, mixture,
  868  or preparation, including its salts, isomers, esters, or ethers,
  869  and salts of isomers, esters, or ethers, whenever the existence
  870  of such salts is possible within any of the following specific
  871  chemical designations, any compound containing a phenethylamine
  872  structure without a beta-keto group, with substitution on the
  873  nitrogen atom of the amino group with a benzyl substituent, with
  874  or without substitution on the phenyl or benzyl ring to any
  875  extent with alkyl, alkoxy, thio, alkylthio, halide, fused
  876  alkylenedioxy, fused furan, fused benzofuran, or fused
  877  tetrahydropyran substituents, whether or not further substituted
  878  on a ring to any extent, with or without substitution at the
  879  alpha position by any alkyl substituent, including, but not
  880  limited to:
  881         a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2
  882  methoxybenzyl)]phenethylamine).
  883         b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2
  884  hydroxybenzyl)]phenethylamine).
  885         c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2
  886  fluorobenzyl)]phenethylamine).
  887         d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3
  888  methylenedioxybenzyl)]phenethylamine).
  889         e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2
  890  methoxybenzyl)]phenethylamine).
  891         f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2
  892  hydroxybenzyl)]phenethylamine).
  893         g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2
  894  fluorobenzyl)]phenethylamine).
  895         h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3
  896  methylenedioxybenzyl)]phenethylamine).
  897         i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2
  898  methoxybenzyl)]phenethylamine).
  899         j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2
  900  methoxybenzyl)]phenethylamine).
  901         k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2
  902  methoxybenzyl)]phenethylamine).
  903         l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2
  904  methoxybenzyl)]phenethylamine).
  905         m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2
  906  hydroxybenzyl)]phenethylamine).
  907         n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2
  908  fluorobenzyl)]phenethylamine).
  909         o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3
  910  methylenedioxybenzyl)]phenethylamine).
  911         p. 25H-NBOMe (2,5-Dimethoxy-[N-(2
  912  methoxybenzyl)]phenethylamine).
  913         q. 25H-NBOH (2,5-Dimethoxy-[N-(2
  914  hydroxybenzyl)]phenethylamine).
  915         r. 25H-NBF (2,5-Dimethoxy-[N-(2
  916  fluorobenzyl)]phenethylamine).
  917         s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2
  918  methoxybenzyl)]phenethylamine),
  919  
  920  which does not include substituted cathinones as described in
  921  subparagraph 191.
  922         194. Substituted Tryptamines.—Unless specifically excepted
  923  or unless listed in another schedule, or contained within a
  924  pharmaceutical product approved by the United States Food and
  925  Drug Administration, any material, compound, mixture, or
  926  preparation containing a 2-(1H-indol-3-yl)ethanamine, for
  927  example tryptamine, structure with or without mono- or di
  928  substitution of the amine nitrogen with alkyl or alkenyl groups,
  929  or by inclusion of the amino nitrogen atom in a cyclic
  930  structure, whether or not substituted at the alpha position with
  931  an alkyl group, whether or not substituted on the indole ring to
  932  any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy
  933  groups, including, but not limited to:
  934         a. Alpha-Ethyltryptamine.
  935         b. Bufotenine.
  936         c. DET (Diethyltryptamine).
  937         d. DMT (Dimethyltryptamine).
  938         e. MET (N-Methyl-N-ethyltryptamine).
  939         f. DALT (N,N-Diallyltryptamine).
  940         g. EiPT (N-Ethyl-N-isopropyltryptamine).
  941         h. MiPT (N-Methyl-N-isopropyltryptamine).
  942         i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
  943         j. 5-Hydroxy-N-methyltryptamine.
  944         k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).
  945         l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
  946         m. Methyltryptamine.
  947         n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
  948         o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
  949         p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
  950         q. DiPT (N,N-Diisopropyltryptamine).
  951         r. DPT (N,N-Dipropyltryptamine).
  952         s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
  953         t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
  954         u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine).
  955         v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine).
  956         w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine).
  957         x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine).
  958         y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N
  959  isopropyltryptamine).
  960         z. Methyl-alpha-ethyltryptamine.
  961         aa. Bromo-DALT (Bromo-N,N-diallyltryptamine),
  962  
  963  which does not include tryptamine, psilocyn as described in
  964  subparagraph 34., or psilocybin as described in subparagraph 33.
  965         195. Substituted Phenylcyclohexylamines.—Unless
  966  specifically excepted or unless listed in another schedule, or
  967  contained within a pharmaceutical product approved by the United
  968  States Food and Drug Administration, any material, compound,
  969  mixture, or preparation containing a phenylcyclohexylamine
  970  structure, with or without any substitution on the phenyl ring,
  971  any substitution on the cyclohexyl ring, any replacement of the
  972  phenyl ring with a thiophenyl or benzothiophenyl ring, with or
  973  without substitution on the amine with alkyl, dialkyl, or alkoxy
  974  substituents, inclusion of the nitrogen in a cyclic structure,
  975  or any combination of the above, including, but not limited to:
  976         a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
  977  (Benocyclidine).
  978         b. PCE (N-Ethyl-1-phenylcyclohexylamine)(Ethylamine analog
  979  of phencyclidine).
  980         c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine)(Pyrrolidine
  981  analog of phencyclidine).
  982         d. PCPr (Phenylcyclohexylpropylamine).
  983         e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)(Thiophene
  984  analog of phencyclidine).
  985         f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)).
  986         g. PCMPA (Phenylcyclohexyl(methoxypropylamine)).
  987         h. Methoxetamine.
  988         i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine).
  989         j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine).
  990         k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine).
  991         l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine).
  992         m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine).
  993         n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine).
  994         o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine).
  995         p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
  996         q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
  997         r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).
  998         196.Mitragynine or 7-Hydroxymitragynine, except for any
  999  drug product approved by the United States Food and Drug
 1000  Administration which contains Mitragynine or 7
 1001  Hydroxymitragynine, including any of their isomers, esters,
 1002  ethers, salts, and salts of isomers, esters, and ethers, if the
 1003  existence of such isomers, esters, ethers, and salts is possible
 1004  within the specific chemical designation.
 1005         Section 2. Subsection (11) is added to section 893.13,
 1006  Florida Statutes, to read:
 1007         893.13 Prohibited acts; penalties.—
 1008         (11)Any prohibited act related to the controlled substance
 1009  described in s. 893.03(1)(c)196. shall be exclusively governed
 1010  by this subsection. A person who sells, delivers, manufactures,
 1011  or brings into this state, or possesses with intent to sell,
 1012  deliver, manufacture, or bring into this state, the controlled
 1013  substance described in s. 893.03(1)(c)196. commits a misdemeanor
 1014  of the first degree, punishable as provided in s. 775.082 or s.
 1015  775.083.
 1016         Section 3. For the purpose of incorporating the amendment
 1017  made by this act to section 893.03, Florida Statutes, in
 1018  references thereto, paragraphs (a) and (g) of subsection (30) of
 1019  section 39.01, Florida Statutes, are reenacted to read:
 1020         39.01 Definitions.—When used in this chapter, unless the
 1021  context otherwise requires:
 1022         (30) “Harm” to a child’s health or welfare can occur when
 1023  any person:
 1024         (a) Inflicts or allows to be inflicted upon the child
 1025  physical, mental, or emotional injury. In determining whether
 1026  harm has occurred, the following factors must be considered in
 1027  evaluating any physical, mental, or emotional injury to a child:
 1028  the age of the child; any prior history of injuries to the
 1029  child; the location of the injury on the body of the child; the
 1030  multiplicity of the injury; and the type of trauma inflicted.
 1031  Such injury includes, but is not limited to:
 1032         1. Willful acts that produce the following specific
 1033  injuries:
 1034         a. Sprains, dislocations, or cartilage damage.
 1035         b. Bone or skull fractures.
 1036         c. Brain or spinal cord damage.
 1037         d. Intracranial hemorrhage or injury to other internal
 1038  organs.
 1039         e. Asphyxiation, suffocation, or drowning.
 1040         f. Injury resulting from the use of a deadly weapon.
 1041         g. Burns or scalding.
 1042         h. Cuts, lacerations, punctures, or bites.
 1043         i. Permanent or temporary disfigurement.
 1044         j. Permanent or temporary loss or impairment of a body part
 1045  or function.
 1046  
 1047  As used in this subparagraph, the term “willful” refers to the
 1048  intent to perform an action, not to the intent to achieve a
 1049  result or to cause an injury.
 1050         2. Purposely giving a child poison, alcohol, drugs, or
 1051  other substances that substantially affect the child’s behavior,
 1052  motor coordination, or judgment or that result in sickness or
 1053  internal injury. For the purposes of this subparagraph, the term
 1054  “drugs” means prescription drugs not prescribed for the child or
 1055  not administered as prescribed, and controlled substances as
 1056  outlined in Schedule I or Schedule II of s. 893.03.
 1057         3. Leaving a child without adult supervision or arrangement
 1058  appropriate for the child’s age or mental or physical condition,
 1059  so that the child is unable to care for the child’s own needs or
 1060  another’s basic needs or is unable to exercise good judgment in
 1061  responding to any kind of physical or emotional crisis.
 1062         4. Inappropriate or excessively harsh disciplinary action
 1063  that is likely to result in physical injury, mental injury as
 1064  defined in this section, or emotional injury. The significance
 1065  of any injury must be evaluated in light of the following
 1066  factors: the age of the child; any prior history of injuries to
 1067  the child; the location of the injury on the body of the child;
 1068  the multiplicity of the injury; and the type of trauma
 1069  inflicted. Corporal discipline may be considered excessive or
 1070  abusive when it results in any of the following or other similar
 1071  injuries:
 1072         a. Sprains, dislocations, or cartilage damage.
 1073         b. Bone or skull fractures.
 1074         c. Brain or spinal cord damage.
 1075         d. Intracranial hemorrhage or injury to other internal
 1076  organs.
 1077         e. Asphyxiation, suffocation, or drowning.
 1078         f. Injury resulting from the use of a deadly weapon.
 1079         g. Burns or scalding.
 1080         h. Cuts, lacerations, punctures, or bites.
 1081         i. Permanent or temporary disfigurement.
 1082         j. Permanent or temporary loss or impairment of a body part
 1083  or function.
 1084         k. Significant bruises or welts.
 1085         (g) Exposes a child to a controlled substance or alcohol.
 1086  Exposure to a controlled substance or alcohol is established by:
 1087         1. A test, administered at birth, which indicated that the
 1088  child’s blood, urine, or meconium contained any amount of
 1089  alcohol or a controlled substance or metabolites of such
 1090  substances, the presence of which was not the result of medical
 1091  treatment administered to the mother or the newborn infant; or
 1092         2. Evidence of extensive, abusive, and chronic use of a
 1093  controlled substance or alcohol by a parent when the child is
 1094  demonstrably adversely affected by such usage.
 1095  
 1096  As used in this paragraph, the term “controlled substance” means
 1097  prescription drugs not prescribed for the parent or not
 1098  administered as prescribed and controlled substances as outlined
 1099  in Schedule I or Schedule II of s. 893.03.
 1100         Section 4. For the purpose of incorporating the amendment
 1101  made by this act to section 893.03, Florida Statutes, in a
 1102  reference thereto, subsection (5) of section 316.193, Florida
 1103  Statutes, is reenacted to read:
 1104         316.193 Driving under the influence; penalties.—
 1105         (5) The court shall place all offenders convicted of
 1106  violating this section on monthly reporting probation and shall
 1107  require completion of a substance abuse course conducted by a
 1108  DUI program licensed by the department under s. 322.292, which
 1109  must include a psychosocial evaluation of the offender. If the
 1110  DUI program refers the offender to an authorized substance abuse
 1111  treatment provider for substance abuse treatment, in addition to
 1112  any sentence or fine imposed under this section, completion of
 1113  all such education, evaluation, and treatment is a condition of
 1114  reporting probation. The offender shall assume reasonable costs
 1115  for such education, evaluation, and treatment. The referral to
 1116  treatment resulting from a psychosocial evaluation shall not be
 1117  waived without a supporting independent psychosocial evaluation
 1118  conducted by an authorized substance abuse treatment provider
 1119  appointed by the court, which shall have access to the DUI
 1120  program’s psychosocial evaluation before the independent
 1121  psychosocial evaluation is conducted. The court shall review the
 1122  results and recommendations of both evaluations before
 1123  determining the request for waiver. The offender shall bear the
 1124  full cost of this procedure. The term “substance abuse” means
 1125  the abuse of alcohol or any substance named or described in
 1126  Schedules I through V of s. 893.03. If an offender referred to
 1127  treatment under this subsection fails to report for or complete
 1128  such treatment or fails to complete the DUI program substance
 1129  abuse education course and evaluation, the DUI program shall
 1130  notify the court and the department of the failure. Upon receipt
 1131  of the notice, the department shall cancel the offender’s
 1132  driving privilege, notwithstanding the terms of the court order
 1133  or any suspension or revocation of the driving privilege. The
 1134  department may temporarily reinstate the driving privilege on a
 1135  restricted basis upon verification from the DUI program that the
 1136  offender is currently participating in treatment and the DUI
 1137  education course and evaluation requirement has been completed.
 1138  If the DUI program notifies the department of the second failure
 1139  to complete treatment, the department shall reinstate the
 1140  driving privilege only after notice of completion of treatment
 1141  from the DUI program. The organization that conducts the
 1142  substance abuse education and evaluation may not provide
 1143  required substance abuse treatment unless a waiver has been
 1144  granted to that organization by the department. A waiver may be
 1145  granted only if the department determines, in accordance with
 1146  its rules, that the service provider that conducts the substance
 1147  abuse education and evaluation is the most appropriate service
 1148  provider and is licensed under chapter 397 or is exempt from
 1149  such licensure. A statistical referral report shall be submitted
 1150  quarterly to the department by each organization authorized to
 1151  provide services under this section.
 1152         Section 5. For the purpose of incorporating the amendment
 1153  made by this act to section 893.03, Florida Statutes, in a
 1154  reference thereto, paragraph (c) of subsection (2) of section
 1155  322.2616, Florida Statutes, is reenacted to read:
 1156         322.2616 Suspension of license; persons under 21 years of
 1157  age; right to review.—
 1158         (2)
 1159         (c) When a driver subject to this section has a blood
 1160  alcohol or breath-alcohol level of 0.05 or higher, the
 1161  suspension shall remain in effect until such time as the driver
 1162  has completed a substance abuse course offered by a DUI program
 1163  licensed by the department. The driver shall assume the
 1164  reasonable costs for the substance abuse course. As part of the
 1165  substance abuse course, the program shall conduct a substance
 1166  abuse evaluation of the driver, and notify the parents or legal
 1167  guardians of drivers under the age of 19 years of the results of
 1168  the evaluation. The term “substance abuse” means the abuse of
 1169  alcohol or any substance named or described in Schedules I
 1170  through V of s. 893.03. If a driver fails to complete the
 1171  substance abuse education course and evaluation, the driver
 1172  license shall not be reinstated by the department.
 1173         Section 6. For the purpose of incorporating the amendment
 1174  made by this act to section 893.03, Florida Statutes, in a
 1175  reference thereto, subsection (5) of section 327.35, Florida
 1176  Statutes, is reenacted to read:
 1177         327.35 Boating under the influence; penalties; “designated
 1178  drivers.”—
 1179         (5) In addition to any sentence or fine, the court shall
 1180  place any offender convicted of violating this section on
 1181  monthly reporting probation and shall require attendance at a
 1182  substance abuse course specified by the court; and the agency
 1183  conducting the course may refer the offender to an authorized
 1184  service provider for substance abuse evaluation and treatment,
 1185  in addition to any sentence or fine imposed under this section.
 1186  The offender shall assume reasonable costs for such education,
 1187  evaluation, and treatment, with completion of all such
 1188  education, evaluation, and treatment being a condition of
 1189  reporting probation. Treatment resulting from a psychosocial
 1190  evaluation may not be waived without a supporting psychosocial
 1191  evaluation conducted by an agency appointed by the court and
 1192  with access to the original evaluation. The offender shall bear
 1193  the cost of this procedure. The term “substance abuse” means the
 1194  abuse of alcohol or any substance named or described in
 1195  Schedules I-V of s. 893.03.
 1196         Section 7. For the purpose of incorporating the amendment
 1197  made by this act to section 893.03, Florida Statutes, in a
 1198  reference thereto, paragraph (b) of subsection (11) of section
 1199  440.102, Florida Statutes, is reenacted to read:
 1200         440.102 Drug-free workplace program requirements.—The
 1201  following provisions apply to a drug-free workplace program
 1202  implemented pursuant to law or to rules adopted by the Agency
 1203  for Health Care Administration:
 1204         (11) PUBLIC EMPLOYEES IN MANDATORY-TESTING OR SPECIAL-RISK
 1205  POSITIONS.—
 1206         (b) An employee who is employed by a public employer in a
 1207  special-risk position may be discharged or disciplined by a
 1208  public employer for the first positive confirmed test result if
 1209  the drug confirmed is an illicit drug under s. 893.03. A
 1210  special-risk employee who is participating in an employee
 1211  assistance program or drug rehabilitation program may not be
 1212  allowed to continue to work in any special-risk or mandatory
 1213  testing position of the public employer, but may be assigned to
 1214  a position other than a mandatory-testing position or placed on
 1215  leave while the employee is participating in the program.
 1216  However, the employee shall be permitted to use any accumulated
 1217  annual leave credits before leave may be ordered without pay.
 1218         Section 8. For the purpose of incorporating the amendment
 1219  made by this act to section 893.03, Florida Statutes, in a
 1220  reference thereto, paragraph (e) of subsection (1) of section
 1221  458.3265, Florida Statutes, is reenacted to read:
 1222         458.3265 Pain-management clinics.—
 1223         (1) REGISTRATION.—
 1224         (e) The department shall deny registration to any pain
 1225  management clinic owned by or with any contractual or employment
 1226  relationship with a physician:
 1227         1. Whose Drug Enforcement Administration number has ever
 1228  been revoked.
 1229         2. Whose application for a license to prescribe, dispense,
 1230  or administer a controlled substance has been denied by any
 1231  jurisdiction.
 1232         3. Who has been convicted of or pleaded guilty or nolo
 1233  contendere to, regardless of adjudication, an offense that
 1234  constitutes a felony for receipt of illicit and diverted drugs,
 1235  including a controlled substance listed in Schedule I, Schedule
 1236  II, Schedule III, Schedule IV, or Schedule V of s. 893.03, in
 1237  this state, any other state, or the United States.
 1238         Section 9. For the purpose of incorporating the amendment
 1239  made by this act to section 893.03, Florida Statutes, in a
 1240  reference thereto, paragraph (e) of subsection (1) of section
 1241  459.0137, Florida Statutes, is reenacted to read:
 1242         459.0137 Pain-management clinics.—
 1243         (1) REGISTRATION.—
 1244         (e) The department shall deny registration to any pain
 1245  management clinic owned by or with any contractual or employment
 1246  relationship with a physician:
 1247         1. Whose Drug Enforcement Administration number has ever
 1248  been revoked.
 1249         2. Whose application for a license to prescribe, dispense,
 1250  or administer a controlled substance has been denied by any
 1251  jurisdiction.
 1252         3. Who has been convicted of or pleaded guilty or nolo
 1253  contendere to, regardless of adjudication, an offense that
 1254  constitutes a felony for receipt of illicit and diverted drugs,
 1255  including a controlled substance listed in Schedule I, Schedule
 1256  II, Schedule III, Schedule IV, or Schedule V of s. 893.03, in
 1257  this state, any other state, or the United States.
 1258         Section 10. For the purpose of incorporating the amendment
 1259  made by this act to section 893.03, Florida Statutes, in
 1260  references thereto, paragraph (a) of subsection (1) and
 1261  subsection (4) of section 782.04, Florida Statutes, are
 1262  reenacted to read:
 1263         782.04 Murder.—
 1264         (1)(a) The unlawful killing of a human being:
 1265         1. When perpetrated from a premeditated design to effect
 1266  the death of the person killed or any human being;
 1267         2. When committed by a person engaged in the perpetration
 1268  of, or in the attempt to perpetrate, any:
 1269         a. Trafficking offense prohibited by s. 893.135(1),
 1270         b. Arson,
 1271         c. Sexual battery,
 1272         d. Robbery,
 1273         e. Burglary,
 1274         f. Kidnapping,
 1275         g. Escape,
 1276         h. Aggravated child abuse,
 1277         i. Aggravated abuse of an elderly person or disabled adult,
 1278         j. Aircraft piracy,
 1279         k. Unlawful throwing, placing, or discharging of a
 1280  destructive device or bomb,
 1281         l. Carjacking,
 1282         m. Home-invasion robbery,
 1283         n. Aggravated stalking,
 1284         o. Murder of another human being,
 1285         p. Resisting an officer with violence to his or her person,
 1286         q. Aggravated fleeing or eluding with serious bodily injury
 1287  or death,
 1288         r. Felony that is an act of terrorism or is in furtherance
 1289  of an act of terrorism,
 1290         s. Human trafficking; or
 1291         3. Which resulted from the unlawful distribution of any
 1292  substance controlled under s. 893.03(1), cocaine as described in
 1293  s. 893.03(2)(a)4., opium or any synthetic or natural salt,
 1294  compound, derivative, or preparation of opium, or methadone by a
 1295  person 18 years of age or older, when such drug is proven to be
 1296  the proximate cause of the death of the user,
 1297  
 1298  is murder in the first degree and constitutes a capital felony,
 1299  punishable as provided in s. 775.082.
 1300         (4) The unlawful killing of a human being, when perpetrated
 1301  without any design to effect death, by a person engaged in the
 1302  perpetration of, or in the attempt to perpetrate, any felony
 1303  other than any:
 1304         (a) Trafficking offense prohibited by s. 893.135(1),
 1305         (b) Arson,
 1306         (c) Sexual battery,
 1307         (d) Robbery,
 1308         (e) Burglary,
 1309         (f) Kidnapping,
 1310         (g) Escape,
 1311         (h) Aggravated child abuse,
 1312         (i) Aggravated abuse of an elderly person or disabled
 1313  adult,
 1314         (j) Aircraft piracy,
 1315         (k) Unlawful throwing, placing, or discharging of a
 1316  destructive device or bomb,
 1317         (l) Unlawful distribution of any substance controlled under
 1318  s. 893.03(1), cocaine as described in s. 893.03(2)(a)4., or
 1319  opium or any synthetic or natural salt, compound, derivative, or
 1320  preparation of opium by a person 18 years of age or older, when
 1321  such drug is proven to be the proximate cause of the death of
 1322  the user,
 1323         (m) Carjacking,
 1324         (n) Home-invasion robbery,
 1325         (o) Aggravated stalking,
 1326         (p) Murder of another human being,
 1327         (q) Aggravated fleeing or eluding with serious bodily
 1328  injury or death,
 1329         (r) Resisting an officer with violence to his or her
 1330  person, or
 1331         (s) Felony that is an act of terrorism or is in furtherance
 1332  of an act of terrorism,
 1333  
 1334  is murder in the third degree and constitutes a felony of the
 1335  second degree, punishable as provided in s. 775.082, s. 775.083,
 1336  or s. 775.084.
 1337         Section 11. For the purpose of incorporating the amendment
 1338  made by this act to section 893.03, Florida Statutes, in a
 1339  reference thereto, paragraph (a) of subsection (2) of section
 1340  787.06, Florida Statutes, is reenacted to read:
 1341         787.06 Human trafficking.—
 1342         (2) As used in this section, the term:
 1343         (a) “Coercion” means:
 1344         1. Using or threatening to use physical force against any
 1345  person;
 1346         2. Restraining, isolating, or confining or threatening to
 1347  restrain, isolate, or confine any person without lawful
 1348  authority and against her or his will;
 1349         3. Using lending or other credit methods to establish a
 1350  debt by any person when labor or services are pledged as a
 1351  security for the debt, if the value of the labor or services as
 1352  reasonably assessed is not applied toward the liquidation of the
 1353  debt, the length and nature of the labor or services are not
 1354  respectively limited and defined;
 1355         4. Destroying, concealing, removing, confiscating,
 1356  withholding, or possessing any actual or purported passport,
 1357  visa, or other immigration document, or any other actual or
 1358  purported government identification document, of any person;
 1359         5. Causing or threatening to cause financial harm to any
 1360  person;
 1361         6. Enticing or luring any person by fraud or deceit; or
 1362         7. Providing a controlled substance as outlined in Schedule
 1363  I or Schedule II of s. 893.03 to any person for the purpose of
 1364  exploitation of that person.
 1365         Section 12. For the purpose of incorporating the amendment
 1366  made by this act to section 893.03, Florida Statutes, in a
 1367  reference thereto, section 817.563, Florida Statutes, is
 1368  reenacted to read:
 1369         817.563 Controlled substance named or described in s.
 1370  893.03; sale of substance in lieu thereof.—It is unlawful for
 1371  any person to agree, consent, or in any manner offer to
 1372  unlawfully sell to any person a controlled substance named or
 1373  described in s. 893.03 and then sell to such person any other
 1374  substance in lieu of such controlled substance. Any person who
 1375  violates this section with respect to:
 1376         (1) A controlled substance named or described in s.
 1377  893.03(1), (2), (3), or (4) is guilty of a felony of the third
 1378  degree, punishable as provided in s. 775.082, s. 775.083, or s.
 1379  775.084.
 1380         (2) A controlled substance named or described in s.
 1381  893.03(5) is guilty of a misdemeanor of the second degree,
 1382  punishable as provided in s. 775.082 or s. 775.083.
 1383         Section 13. For the purpose of incorporating the amendment
 1384  made by this act to section 893.03, Florida Statutes, in
 1385  references thereto, paragraph (a) of subsection (1) and
 1386  subsection (2) of section 831.31, Florida Statutes, are
 1387  reenacted to read:
 1388         831.31 Counterfeit controlled substance; sale, manufacture,
 1389  delivery, or possession with intent to sell, manufacture, or
 1390  deliver.—
 1391         (1) It is unlawful for any person to sell, manufacture, or
 1392  deliver, or to possess with intent to sell, manufacture, or
 1393  deliver, a counterfeit controlled substance. Any person who
 1394  violates this subsection with respect to:
 1395         (a) A controlled substance named or described in s.
 1396  893.03(1), (2), (3), or (4) is guilty of a felony of the third
 1397  degree, punishable as provided in s. 775.082, s. 775.083, or s.
 1398  775.084.
 1399         (2) For purposes of this section, “counterfeit controlled
 1400  substance” means:
 1401         (a) A controlled substance named or described in s. 893.03
 1402  which, or the container or labeling of which, without
 1403  authorization bears the trademark, trade name, or other
 1404  identifying mark, imprint, or number, or any likeness thereof,
 1405  of a manufacturer other than the person who in fact manufactured
 1406  the controlled substance; or
 1407         (b) Any substance which is falsely identified as a
 1408  controlled substance named or described in s. 893.03.
 1409         Section 14. For the purpose of incorporating the amendment
 1410  made by this act to section 893.03, Florida Statutes, in a
 1411  reference thereto, paragraph (c) of subsection (1) of section
 1412  856.015, Florida Statutes, is reenacted to read:
 1413         856.015 Open house parties.—
 1414         (1) Definitions.—As used in this section:
 1415         (c) “Drug” means a controlled substance, as that term is
 1416  defined in ss. 893.02(4) and 893.03.
 1417         Section 15. For the purpose of incorporating the amendment
 1418  made by this act to section 893.03, Florida Statutes, in a
 1419  reference thereto, subsection (4) of section 893.02, Florida
 1420  Statutes, is reenacted to read:
 1421         893.02 Definitions.—The following words and phrases as used
 1422  in this chapter shall have the following meanings, unless the
 1423  context otherwise requires:
 1424         (4) “Controlled substance” means any substance named or
 1425  described in Schedules I-V of s. 893.03. Laws controlling the
 1426  manufacture, distribution, preparation, dispensing, or
 1427  administration of such substances are drug abuse laws.
 1428         Section 16. For the purpose of incorporating the amendment
 1429  made by this act to section 893.03, Florida Statutes, in
 1430  references thereto, subsection (2), paragraph (a) of subsection
 1431  (7), and paragraph (a) of subsection (8) of section 893.035,
 1432  Florida Statutes, are reenacted to read:
 1433         893.035 Control of new substances; findings of fact;
 1434  delegation of authority to Attorney General to control
 1435  substances by rule.—
 1436         (2) The Attorney General shall apply the provisions of this
 1437  section to any substance not currently controlled under the
 1438  provisions of s. 893.03. The Attorney General may by rule:
 1439         (a) Add a substance to a schedule established by s. 893.03,
 1440  or transfer a substance between schedules, if he or she finds
 1441  that it has a potential for abuse and he or she makes with
 1442  respect to it the other findings appropriate for classification
 1443  in the particular schedule under s. 893.03 in which it is to be
 1444  placed.
 1445         (b) Remove a substance previously added to a schedule if he
 1446  or she finds the substance does not meet the requirements for
 1447  inclusion in that schedule.
 1448  
 1449  Rules adopted under this section shall be made pursuant to the
 1450  rulemaking procedures prescribed by chapter 120.
 1451         (7)(a) If the Attorney General finds that the scheduling of
 1452  a substance in Schedule I of s. 893.03 on a temporary basis is
 1453  necessary to avoid an imminent hazard to the public safety, he
 1454  or she may by rule and without regard to the requirements of
 1455  subsection (5) relating to the Department of Health and the
 1456  Department of Law Enforcement schedule such substance in
 1457  Schedule I if the substance is not listed in any other schedule
 1458  of s. 893.03. The Attorney General shall be required to
 1459  consider, with respect to his or her finding of imminent hazard
 1460  to the public safety, only those factors set forth in paragraphs
 1461  (3)(a) and (4)(d), (e), and (f), including actual abuse,
 1462  diversion from legitimate channels, and clandestine importation,
 1463  manufacture, or distribution.
 1464         (8)(a) Upon the effective date of a rule adopted pursuant
 1465  to this section adding or transferring a substance to a schedule
 1466  under s. 893.03, such substance shall be deemed included in that
 1467  schedule, and all provisions of this chapter applicable to
 1468  substances in that schedule shall be deemed applicable to such
 1469  substance.
 1470         Section 17. For the purpose of incorporating the amendment
 1471  made by this act to section 893.03, Florida Statutes, in
 1472  references thereto, paragraph (a) of subsection (2) and
 1473  subsection (5) of section 893.0356, Florida Statutes, are
 1474  reenacted to read:
 1475         893.0356 Control of new substances; findings of fact;
 1476  “controlled substance analog” defined.—
 1477         (2)(a) As used in this section, “controlled substance
 1478  analog” means a substance which, due to its chemical structure
 1479  and potential for abuse, meets the following criteria:
 1480         1. Is substantially similar to that of a controlled
 1481  substance listed in Schedule I or Schedule II of s. 893.03; and
 1482         2. Has a stimulant, depressant, or hallucinogenic effect on
 1483  the central nervous system or is represented or intended to have
 1484  a stimulant, depressant, or hallucinogenic effect on the central
 1485  nervous system substantially similar to or greater than that of
 1486  a controlled substance listed in Schedule I or Schedule II of s.
 1487  893.03.
 1488         (5) A controlled substance analog shall, for purposes of
 1489  drug abuse prevention and control, be treated as the highest
 1490  scheduled controlled substance of which it is a controlled
 1491  substance analog in s. 893.03.
 1492         Section 18. For the purpose of incorporating the amendment
 1493  made by this act to section 893.03, Florida Statutes, in a
 1494  reference thereto, paragraph (d) of subsection (1) of section
 1495  893.05, Florida Statutes, is reenacted to read:
 1496         893.05 Practitioners and persons administering controlled
 1497  substances in their absence.—
 1498         (1)
 1499         (d) A certified optometrist licensed under chapter 463 may
 1500  not administer or prescribe a controlled substance listed in
 1501  Schedule I or Schedule II of s. 893.03.
 1502         Section 19. For the purpose of incorporating the amendment
 1503  made by this act to section 893.03, Florida Statutes, in
 1504  references thereto, paragraphs (b), (c), and (d) of subsection
 1505  (2) of section 893.12, Florida Statutes, are reenacted to read:
 1506         893.12 Contraband; seizure, forfeiture, sale.—
 1507         (2)
 1508         (b) All real property, including any right, title,
 1509  leasehold interest, and other interest in the whole of any lot
 1510  or tract of land and any appurtenances or improvements, which
 1511  real property is used, or intended to be used, in any manner or
 1512  part, to commit or to facilitate the commission of, or which
 1513  real property is acquired with proceeds obtained as a result of,
 1514  a violation of any provision of this chapter related to a
 1515  controlled substance described in s. 893.03(1) or (2) may be
 1516  seized and forfeited as provided by the Florida Contraband
 1517  Forfeiture Act except that no property shall be forfeited under
 1518  this paragraph to the extent of an interest of an owner or
 1519  lienholder by reason of any act or omission established by that
 1520  owner or lienholder to have been committed or omitted without
 1521  the knowledge or consent of that owner or lienholder.
 1522         (c) All moneys, negotiable instruments, securities, and
 1523  other things of value furnished or intended to be furnished by
 1524  any person in exchange for a controlled substance described in
 1525  s. 893.03(1) or (2) or a listed chemical in violation of any
 1526  provision of this chapter, all proceeds traceable to such an
 1527  exchange, and all moneys, negotiable instruments, and securities
 1528  used or intended to be used to facilitate any violation of any
 1529  provision of this chapter or which are acquired with proceeds
 1530  obtained in violation of any provision of this chapter may be
 1531  seized and forfeited as provided by the Florida Contraband
 1532  Forfeiture Act, except that no property shall be forfeited under
 1533  this paragraph to the extent of an interest of an owner or
 1534  lienholder by reason of any act or omission established by that
 1535  owner or lienholder to have been committed or omitted without
 1536  the knowledge or consent of that owner or lienholder.
 1537         (d) All books, records, and research, including formulas,
 1538  microfilm, tapes, and data which are used, or intended for use,
 1539  or which are acquired with proceeds obtained, in violation of
 1540  any provision of this chapter related to a controlled substance
 1541  described in s. 893.03(1) or (2) or a listed chemical may be
 1542  seized and forfeited as provided by the Florida Contraband
 1543  Forfeiture Act.
 1544         Section 20. For the purpose of incorporating the amendment
 1545  made by this act to section 893.03, Florida Statutes, in
 1546  references thereto, paragraphs (a), (c), (d), (e), (f), and (h)
 1547  of subsection (1), paragraph (a) of subsection (2), paragraph
 1548  (b) of subsection (4), paragraph (b) of subsection (5), and
 1549  paragraph (a) of subsection (7) of section 893.13, Florida
 1550  Statutes, are reenacted to read:
 1551         893.13 Prohibited acts; penalties.—
 1552         (1)(a) Except as authorized by this chapter and chapter
 1553  499, a person may not sell, manufacture, or deliver, or possess
 1554  with intent to sell, manufacture, or deliver, a controlled
 1555  substance. A person who violates this provision with respect to:
 1556         1. A controlled substance named or described in s.
 1557  893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
 1558  commits a felony of the second degree, punishable as provided in
 1559  s. 775.082, s. 775.083, or s. 775.084.
 1560         2. A controlled substance named or described in s.
 1561  893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
 1562  (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
 1563  the third degree, punishable as provided in s. 775.082, s.
 1564  775.083, or s. 775.084.
 1565         3. A controlled substance named or described in s.
 1566  893.03(5) commits a misdemeanor of the first degree, punishable
 1567  as provided in s. 775.082 or s. 775.083.
 1568         (c) Except as authorized by this chapter, a person may not
 1569  sell, manufacture, or deliver, or possess with intent to sell,
 1570  manufacture, or deliver, a controlled substance in, on, or
 1571  within 1,000 feet of the real property comprising a child care
 1572  facility as defined in s. 402.302 or a public or private
 1573  elementary, middle, or secondary school between the hours of 6
 1574  a.m. and 12 midnight, or at any time in, on, or within 1,000
 1575  feet of real property comprising a state, county, or municipal
 1576  park, a community center, or a publicly owned recreational
 1577  facility. As used in this paragraph, the term “community center”
 1578  means a facility operated by a nonprofit community-based
 1579  organization for the provision of recreational, social, or
 1580  educational services to the public. A person who violates this
 1581  paragraph with respect to:
 1582         1. A controlled substance named or described in s.
 1583  893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
 1584  commits a felony of the first degree, punishable as provided in
 1585  s. 775.082, s. 775.083, or s. 775.084. The defendant must be
 1586  sentenced to a minimum term of imprisonment of 3 calendar years
 1587  unless the offense was committed within 1,000 feet of the real
 1588  property comprising a child care facility as defined in s.
 1589  402.302.
 1590         2. A controlled substance named or described in s.
 1591  893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
 1592  (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
 1593  the second degree, punishable as provided in s. 775.082, s.
 1594  775.083, or s. 775.084.
 1595         3. Any other controlled substance, except as lawfully sold,
 1596  manufactured, or delivered, must be sentenced to pay a $500 fine
 1597  and to serve 100 hours of public service in addition to any
 1598  other penalty prescribed by law.
 1599  
 1600  This paragraph does not apply to a child care facility unless
 1601  the owner or operator of the facility posts a sign that is not
 1602  less than 2 square feet in size with a word legend identifying
 1603  the facility as a licensed child care facility and that is
 1604  posted on the property of the child care facility in a
 1605  conspicuous place where the sign is reasonably visible to the
 1606  public.
 1607         (d) Except as authorized by this chapter, a person may not
 1608  sell, manufacture, or deliver, or possess with intent to sell,
 1609  manufacture, or deliver, a controlled substance in, on, or
 1610  within 1,000 feet of the real property comprising a public or
 1611  private college, university, or other postsecondary educational
 1612  institution. A person who violates this paragraph with respect
 1613  to:
 1614         1. A controlled substance named or described in s.
 1615  893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
 1616  commits a felony of the first degree, punishable as provided in
 1617  s. 775.082, s. 775.083, or s. 775.084.
 1618         2. A controlled substance named or described in s.
 1619  893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
 1620  (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
 1621  the second degree, punishable as provided in s. 775.082, s.
 1622  775.083, or s. 775.084.
 1623         3. Any other controlled substance, except as lawfully sold,
 1624  manufactured, or delivered, must be sentenced to pay a $500 fine
 1625  and to serve 100 hours of public service in addition to any
 1626  other penalty prescribed by law.
 1627         (e) Except as authorized by this chapter, a person may not
 1628  sell, manufacture, or deliver, or possess with intent to sell,
 1629  manufacture, or deliver, a controlled substance not authorized
 1630  by law in, on, or within 1,000 feet of a physical place for
 1631  worship at which a church or religious organization regularly
 1632  conducts religious services or within 1,000 feet of a
 1633  convenience business as defined in s. 812.171. A person who
 1634  violates this paragraph with respect to:
 1635         1. A controlled substance named or described in s.
 1636  893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
 1637  commits a felony of the first degree, punishable as provided in
 1638  s. 775.082, s. 775.083, or s. 775.084.
 1639         2. A controlled substance named or described in s.
 1640  893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
 1641  (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
 1642  the second degree, punishable as provided in s. 775.082, s.
 1643  775.083, or s. 775.084.
 1644         3. Any other controlled substance, except as lawfully sold,
 1645  manufactured, or delivered, must be sentenced to pay a $500 fine
 1646  and to serve 100 hours of public service in addition to any
 1647  other penalty prescribed by law.
 1648         (f) Except as authorized by this chapter, a person may not
 1649  sell, manufacture, or deliver, or possess with intent to sell,
 1650  manufacture, or deliver, a controlled substance in, on, or
 1651  within 1,000 feet of the real property comprising a public
 1652  housing facility at any time. As used in this section, the term
 1653  “real property comprising a public housing facility” means real
 1654  property, as defined in s. 421.03(12), of a public corporation
 1655  created as a housing authority pursuant to part I of chapter
 1656  421. A person who violates this paragraph with respect to:
 1657         1. A controlled substance named or described in s.
 1658  893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
 1659  commits a felony of the first degree, punishable as provided in
 1660  s. 775.082, s. 775.083, or s. 775.084.
 1661         2. A controlled substance named or described in s.
 1662  893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
 1663  (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
 1664  the second degree, punishable as provided in s. 775.082, s.
 1665  775.083, or s. 775.084.
 1666         3. Any other controlled substance, except as lawfully sold,
 1667  manufactured, or delivered, must be sentenced to pay a $500 fine
 1668  and to serve 100 hours of public service in addition to any
 1669  other penalty prescribed by law.
 1670         (h) Except as authorized by this chapter, a person may not
 1671  sell, manufacture, or deliver, or possess with intent to sell,
 1672  manufacture, or deliver, a controlled substance in, on, or
 1673  within 1,000 feet of the real property comprising an assisted
 1674  living facility, as that term is used in chapter 429. A person
 1675  who violates this paragraph with respect to:
 1676         1. A controlled substance named or described in s.
 1677  893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
 1678  commits a felony of the first degree, punishable as provided in
 1679  s. 775.082, s. 775.083, or s. 775.084.
 1680         2. A controlled substance named or described in s.
 1681  893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
 1682  (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
 1683  the second degree, punishable as provided in s. 775.082, s.
 1684  775.083, or s. 775.084.
 1685         3. Any other controlled substance, except as lawfully sold,
 1686  manufactured, or delivered, must be sentenced to pay a $500 fine
 1687  and to serve 100 hours of public service in addition to any
 1688  other penalty prescribed by law.
 1689         (2)(a) Except as authorized by this chapter and chapter
 1690  499, a person may not purchase, or possess with intent to
 1691  purchase, a controlled substance. A person who violates this
 1692  provision with respect to:
 1693         1. A controlled substance named or described in s.
 1694  893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4.
 1695  commits a felony of the second degree, punishable as provided in
 1696  s. 775.082, s. 775.083, or s. 775.084.
 1697         2. A controlled substance named or described in s.
 1698  893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
 1699  (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
 1700  the third degree, punishable as provided in s. 775.082, s.
 1701  775.083, or s. 775.084.
 1702         3. A controlled substance named or described in s.
 1703  893.03(5) commits a misdemeanor of the first degree, punishable
 1704  as provided in s. 775.082 or s. 775.083.
 1705         (4) Except as authorized by this chapter, a person 18 years
 1706  of age or older may not deliver any controlled substance to a
 1707  person younger than 18 years of age, use or hire a person
 1708  younger than 18 years of age as an agent or employee in the sale
 1709  or delivery of such a substance, or use such person to assist in
 1710  avoiding detection or apprehension for a violation of this
 1711  chapter. A person who violates this paragraph with respect to:
 1712         (b) A controlled substance named or described in s.
 1713  893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
 1714  (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
 1715  the second degree, punishable as provided in s. 775.082, s.
 1716  775.083, or s. 775.084.
 1717  
 1718  Imposition of sentence may not be suspended or deferred, and the
 1719  person so convicted may not be placed on probation.
 1720         (5) A person may not bring into this state any controlled
 1721  substance unless the possession of such controlled substance is
 1722  authorized by this chapter or unless such person is licensed to
 1723  do so by the appropriate federal agency. A person who violates
 1724  this provision with respect to:
 1725         (b) A controlled substance named or described in s.
 1726  893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6.,
 1727  (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) commits a felony of
 1728  the third degree, punishable as provided in s. 775.082, s.
 1729  775.083, or s. 775.084.
 1730         (7)(a) A person may not:
 1731         1. Distribute or dispense a controlled substance in
 1732  violation of this chapter.
 1733         2. Refuse or fail to make, keep, or furnish any record,
 1734  notification, order form, statement, invoice, or information
 1735  required under this chapter.
 1736         3. Refuse entry into any premises for any inspection or
 1737  refuse to allow any inspection authorized by this chapter.
 1738         4. Distribute a controlled substance named or described in
 1739  s. 893.03(1) or (2) except pursuant to an order form as required
 1740  by s. 893.06.
 1741         5. Keep or maintain any store, shop, warehouse, dwelling,
 1742  building, vehicle, boat, aircraft, or other structure or place
 1743  which is resorted to by persons using controlled substances in
 1744  violation of this chapter for the purpose of using these
 1745  substances, or which is used for keeping or selling them in
 1746  violation of this chapter.
 1747         6. Use to his or her own personal advantage, or reveal, any
 1748  information obtained in enforcement of this chapter except in a
 1749  prosecution or administrative hearing for a violation of this
 1750  chapter.
 1751         7. Possess a prescription form unless it has been signed by
 1752  the practitioner whose name appears printed thereon and
 1753  completed. This subparagraph does not apply if the person in
 1754  possession of the form is the practitioner whose name appears
 1755  printed thereon, an agent or employee of that practitioner, a
 1756  pharmacist, or a supplier of prescription forms who is
 1757  authorized by that practitioner to possess those forms.
 1758         8. Withhold information from a practitioner from whom the
 1759  person seeks to obtain a controlled substance or a prescription
 1760  for a controlled substance that the person making the request
 1761  has received a controlled substance or a prescription for a
 1762  controlled substance of like therapeutic use from another
 1763  practitioner within the previous 30 days.
 1764         9. Acquire or obtain, or attempt to acquire or obtain,
 1765  possession of a controlled substance by misrepresentation,
 1766  fraud, forgery, deception, or subterfuge.
 1767         10. Affix any false or forged label to a package or
 1768  receptacle containing a controlled substance.
 1769         11. Furnish false or fraudulent material information in, or
 1770  omit any material information from, any report or other document
 1771  required to be kept or filed under this chapter or any record
 1772  required to be kept by this chapter.
 1773         12. Store anhydrous ammonia in a container that is not
 1774  approved by the United States Department of Transportation to
 1775  hold anhydrous ammonia or is not constructed in accordance with
 1776  sound engineering, agricultural, or commercial practices.
 1777         13. With the intent to obtain a controlled substance or
 1778  combination of controlled substances that are not medically
 1779  necessary for the person or an amount of a controlled substance
 1780  or substances that is not medically necessary for the person,
 1781  obtain or attempt to obtain from a practitioner a controlled
 1782  substance or a prescription for a controlled substance by
 1783  misrepresentation, fraud, forgery, deception, subterfuge, or
 1784  concealment of a material fact. For purposes of this
 1785  subparagraph, a material fact includes whether the person has an
 1786  existing prescription for a controlled substance issued for the
 1787  same period of time by another practitioner or as described in
 1788  subparagraph 8.
 1789         Section 21. For the purpose of incorporating the amendment
 1790  made by this act to section 893.03, Florida Statutes, in
 1791  references thereto, paragraphs (b), (c), and (e) of subsection
 1792  (3) of section 921.0022, Florida Statutes, are reenacted to
 1793  read:
 1794         921.0022 Criminal Punishment Code; offense severity ranking
 1795  chart.—
 1796         (3) OFFENSE SEVERITY RANKING CHART
 1797         (b) LEVEL 2
 1798  
 1799  
 1800  FloridaStatute    FelonyDegree           Description            
 1801  379.2431 (1)(e)3.    3rd   Possession of 11 or fewer marine turtle eggs in violation of the Marine Turtle Protection Act.
 1802  379.2431 (1)(e)4.    3rd   Possession of more than 11 marine turtle eggs in violation of the Marine Turtle Protection Act.
 1803  403.413(6)(c)        3rd   Dumps waste litter exceeding 500 lbs. in weight or 100 cubic feet in volume or any quantity for commercial purposes, or hazardous waste.
 1804  517.07(2)            3rd   Failure to furnish a prospectus meeting requirements.
 1805  590.28(1)            3rd   Intentional burning of lands.     
 1806  784.05(3)            3rd   Storing or leaving a loaded firearm within reach of minor who uses it to inflict injury or death.
 1807  787.04(1)            3rd   In violation of court order, take, entice, etc., minor beyond state limits.
 1808  806.13(1)(b)3.       3rd   Criminal mischief; damage $1,000 or more to public communication or any other public service.
 1809  810.061(2)           3rd   Impairing or impeding telephone or power to a dwelling; facilitating or furthering burglary.
 1810  810.09(2)(e)         3rd   Trespassing on posted commercial horticulture property.
 1811  812.014(2)(c)1.      3rd   Grand theft, 3rd degree; $300 or more but less than $5,000.
 1812  812.014(2)(d)        3rd   Grand theft, 3rd degree; $100 or more but less than $300, taken from unenclosed curtilage of dwelling.
 1813  812.015(7)           3rd   Possession, use, or attempted use of an antishoplifting or inventory control device countermeasure.
 1814  817.234(1)(a)2.      3rd   False statement in support of insurance claim.
 1815  817.481(3)(a)        3rd   Obtain credit or purchase with false, expired, counterfeit, etc., credit card, value over $300.
 1816  817.52(3)            3rd   Failure to redeliver hired vehicle.
 1817  817.54               3rd   With intent to defraud, obtain mortgage note, etc., by false representation.
 1818  817.60(5)            3rd   Dealing in credit cards of another.
 1819  817.60(6)(a)         3rd   Forgery; purchase goods, services with false card.
 1820  817.61               3rd   Fraudulent use of credit cards over $100 or more within 6 months.
 1821  826.04               3rd   Knowingly marries or has sexual intercourse with person to whom related.
 1822  831.01               3rd   Forgery.                          
 1823  831.02               3rd   Uttering forged instrument; utters or publishes alteration with intent to defraud.
 1824  831.07               3rd   Forging bank bills, checks, drafts, or promissory notes.
 1825  831.08               3rd   Possessing 10 or more forged notes, bills, checks, or drafts.
 1826  831.09               3rd   Uttering forged notes, bills, checks, drafts, or promissory notes.
 1827  831.11               3rd   Bringing into the state forged bank bills, checks, drafts, or notes.
 1828  832.05(3)(a)         3rd   Cashing or depositing item with intent to defraud.
 1829  843.08               3rd   False personation.                
 1830  893.13(2)(a)2.       3rd   Purchase of any s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) drugs other than cannabis.
 1831  893.147(2)           3rd   Manufacture or delivery of drug paraphernalia.
 1832         (c) LEVEL 3
 1833  
 1834  
 1835  FloridaStatute    FelonyDegree           Description            
 1836  119.10(2)(b)         3rd   Unlawful use of confidential information from police reports.
 1837  316.066 (3)(b)-(d)   3rd   Unlawfully obtaining or using confidential crash reports.
 1838  316.193(2)(b)        3rd   Felony DUI, 3rd conviction.       
 1839  316.1935(2)          3rd   Fleeing or attempting to elude law enforcement officer in patrol vehicle with siren and lights activated.
 1840  319.30(4)            3rd   Possession by junkyard of motor vehicle with identification number plate removed.
 1841  319.33(1)(a)         3rd   Alter or forge any certificate of title to a motor vehicle or mobile home.
 1842  319.33(1)(c)         3rd   Procure or pass title on stolen vehicle.
 1843  319.33(4)            3rd   With intent to defraud, possess, sell, etc., a blank, forged, or unlawfully obtained title or registration.
 1844  327.35(2)(b)         3rd   Felony BUI.                       
 1845  328.05(2)            3rd   Possess, sell, or counterfeit fictitious, stolen, or fraudulent titles or bills of sale of vessels.
 1846  328.07(4)            3rd   Manufacture, exchange, or possess vessel with counterfeit or wrong ID number.
 1847  376.302(5)           3rd   Fraud related to reimbursement for cleanup expenses under the Inland Protection Trust Fund.
 1848  379.2431 (1)(e)5.    3rd   Taking, disturbing, mutilating, destroying, causing to be destroyed, transferring, selling, offering to sell, molesting, or harassing marine turtles, marine turtle eggs, or marine turtle nests in violation of the Marine Turtle Protection Act.
 1849  379.2431 (1)(e)6.    3rd   Soliciting to commit or conspiring to commit a violation of the Marine Turtle Protection Act.
 1850  400.9935(4)(a) or (b)   3rd   Operating a clinic, or offering services requiring licensure, without a license.
 1851  400.9935(4)(e)       3rd   Filing a false license application or other required information or failing to report information.
 1852  440.1051(3)          3rd   False report of workers’ compensation fraud or retaliation for making such a report.
 1853  501.001(2)(b)        2nd   Tampers with a consumer product or the container using materially false/misleading information.
 1854  624.401(4)(a)        3rd   Transacting insurance without a certificate of authority.
 1855  624.401(4)(b)1.      3rd   Transacting insurance without a certificate of authority; premium collected less than $20,000.
 1856  626.902(1)(a) & (b)   3rd   Representing an unauthorized insurer.
 1857  697.08               3rd   Equity skimming.                  
 1858  790.15(3)            3rd   Person directs another to discharge firearm from a vehicle.
 1859  806.10(1)            3rd   Maliciously injure, destroy, or interfere with vehicles or equipment used in firefighting.
 1860  806.10(2)            3rd   Interferes with or assaults firefighter in performance of duty.
 1861  810.09(2)(c)         3rd   Trespass on property other than structure or conveyance armed with firearm or dangerous weapon.
 1862  812.014(2)(c)2.      3rd   Grand theft; $5,000 or more but less than $10,000.
 1863  812.0145(2)(c)       3rd   Theft from person 65 years of age or older; $300 or more but less than $10,000.
 1864  815.04(5)(b)         2nd   Computer offense devised to defraud or obtain property.
 1865  817.034(4)(a)3.      3rd   Engages in scheme to defraud (Florida Communications Fraud Act), property valued at less than $20,000.
 1866  817.233              3rd   Burning to defraud insurer.       
 1867  817.234 (8)(b) & (c)   3rd   Unlawful solicitation of persons involved in motor vehicle accidents.
 1868  817.234(11)(a)       3rd   Insurance fraud; property value less than $20,000.
 1869  817.236              3rd   Filing a false motor vehicle insurance application.
 1870  817.2361             3rd   Creating, marketing, or presenting a false or fraudulent motor vehicle insurance card.
 1871  817.413(2)           3rd   Sale of used goods as new.        
 1872  817.505(4)           3rd   Patient brokering.                
 1873  828.12(2)            3rd   Tortures any animal with intent to inflict intense pain, serious physical injury, or death.
 1874  831.28(2)(a)         3rd   Counterfeiting a payment instrument with intent to defraud or possessing a counterfeit payment instrument.
 1875  831.29               2nd   Possession of instruments for counterfeiting driver licenses or identification cards.
 1876  838.021(3)(b)        3rd   Threatens unlawful harm to public servant.
 1877  843.19               3rd   Injure, disable, or kill police dog or horse.
 1878  860.15(3)            3rd   Overcharging for repairs and parts.
 1879  870.01(2)            3rd   Riot; inciting or encouraging.    
 1880  893.13(1)(a)2.       3rd   Sell, manufacture, or deliver cannabis (or other s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) drugs).
 1881  893.13(1)(d)2.       2nd   Sell, manufacture, or deliver s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) drugs within 1,000 feet of university.
 1882  893.13(1)(f)2.       2nd   Sell, manufacture, or deliver s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) drugs within 1,000 feet of public housing facility.
 1883  893.13(4)(c)         3rd   Use or hire of minor; deliver to minor other controlled substances.
 1884  893.13(6)(a)         3rd   Possession of any controlled substance other than felony possession of cannabis.
 1885  893.13(7)(a)8.       3rd   Withhold information from practitioner regarding previous receipt of or prescription for a controlled substance.
 1886  893.13(7)(a)9.       3rd   Obtain or attempt to obtain controlled substance by fraud, forgery, misrepresentation, etc.
 1887  893.13(7)(a)10.      3rd   Affix false or forged label to package of controlled substance.
 1888  893.13(7)(a)11.      3rd   Furnish false or fraudulent material information on any document or record required by chapter 893.
 1889  893.13(8)(a)1.       3rd   Knowingly assist a patient, other person, or owner of an animal in obtaining a controlled substance through deceptive, untrue, or fraudulent representations in or related to the practitioner’s practice.
 1890  893.13(8)(a)2.       3rd   Employ a trick or scheme in the practitioner’s practice to assist a patient, other person, or owner of an animal in obtaining a controlled substance.
 1891  893.13(8)(a)3.       3rd   Knowingly write a prescription for a controlled substance for a fictitious person.
 1892  893.13(8)(a)4.       3rd   Write a prescription for a controlled substance for a patient, other person, or an animal if the sole purpose of writing the prescription is a monetary benefit for the practitioner.
 1893  918.13(1)(a)         3rd   Alter, destroy, or conceal investigation evidence.
 1894  944.47 (1)(a)1. & 2.   3rd   Introduce contraband to correctional facility.
 1895  944.47(1)(c)         2nd   Possess contraband while upon the grounds of a correctional institution.
 1896  985.721              3rd   Escapes from a juvenile facility (secure detention or residential commitment facility).
 1897         (e) LEVEL 5
 1898  
 1899  
 1900  FloridaStatute    FelonyDegree           Description            
 1901  316.027(2)(a)        3rd   Accidents involving personal injuries other than serious bodily injury, failure to stop; leaving scene.
 1902  316.1935(4)(a)       2nd   Aggravated fleeing or eluding.    
 1903  316.80(2)            2nd   Unlawful conveyance of fuel; obtaining fuel fraudulently.
 1904  322.34(6)            3rd   Careless operation of motor vehicle with suspended license, resulting in death or serious bodily injury.
 1905  327.30(5)            3rd   Vessel accidents involving personal injury; leaving scene.
 1906  379.365(2)(c)1.      3rd   Violation of rules relating to: willful molestation of stone crab traps, lines, or buoys; illegal bartering, trading, or sale, conspiring or aiding in such barter, trade, or sale, or supplying, agreeing to supply, aiding in supplying, or giving away stone crab trap tags or certificates; making, altering, forging, counterfeiting, or reproducing stone crab trap tags; possession of forged, counterfeit, or imitation stone crab trap tags; and engaging in the commercial harvest of stone crabs while license is suspended or revoked.
 1907  379.367(4)           3rd   Willful molestation of a commercial harvester’s spiny lobster trap, line, or buoy.
 1908  379.407(5)(b)3.      3rd   Possession of 100 or more undersized spiny lobsters.
 1909  381.0041(11)(b)      3rd   Donate blood, plasma, or organs knowing HIV positive.
 1910  440.10(1)(g)         2nd   Failure to obtain workers’ compensation coverage.
 1911  440.105(5)           2nd   Unlawful solicitation for the purpose of making workers’ compensation claims.
 1912  440.381(2)           2nd   Submission of false, misleading, or incomplete information with the purpose of avoiding or reducing workers’ compensation premiums.
 1913  624.401(4)(b)2.      2nd   Transacting insurance without a certificate or authority; premium collected $20,000 or more but less than $100,000.
 1914  626.902(1)(c)        2nd   Representing an unauthorized insurer; repeat offender.
 1915  790.01(2)            3rd   Carrying a concealed firearm.     
 1916  790.162              2nd   Threat to throw or discharge destructive device.
 1917  790.163(1)           2nd   False report of bomb, explosive, weapon of mass destruction, or use of firearms in violent manner.
 1918  790.221(1)           2nd   Possession of short-barreled shotgun or machine gun.
 1919  790.23               2nd   Felons in possession of firearms, ammunition, or electronic weapons or devices.
 1920  796.05(1)            2nd   Live on earnings of a prostitute; 1st offense.
 1921  800.04(6)(c)         3rd   Lewd or lascivious conduct; offender less than 18 years of age.
 1922  800.04(7)(b)         2nd   Lewd or lascivious exhibition; offender 18 years of age or older.
 1923  806.111(1)           3rd   Possess, manufacture, or dispense fire bomb with intent to damage any structure or property.
 1924  812.0145(2)(b)       2nd   Theft from person 65 years of age or older; $10,000 or more but less than $50,000.
 1925  812.015(8)           3rd   Retail theft; property stolen is valued at $300 or more and one or more specified acts.
 1926  812.019(1)           2nd   Stolen property; dealing in or trafficking in.
 1927  812.131(2)(b)        3rd   Robbery by sudden snatching.      
 1928  812.16(2)            3rd   Owning, operating, or conducting a chop shop.
 1929  817.034(4)(a)2.      2nd   Communications fraud, value $20,000 to $50,000.
 1930  817.234(11)(b)       2nd   Insurance fraud; property value $20,000 or more but less than $100,000.
 1931  817.2341(1), (2)(a) & (3)(a)   3rd   Filing false financial statements, making false entries of material fact or false statements regarding property values relating to the solvency of an insuring entity.
 1932  817.568(2)(b)        2nd   Fraudulent use of personal identification information; value of benefit, services received, payment avoided, or amount of injury or fraud, $5,000 or more or use of personal identification information of 10 or more persons.
 1933  817.611(2)(a)        2nd   Traffic in or possess 5 to 14 counterfeit credit cards or related documents.
 1934  817.625(2)(b)        2nd   Second or subsequent fraudulent use of scanning device or reencoder.
 1935  825.1025(4)          3rd   Lewd or lascivious exhibition in the presence of an elderly person or disabled adult.
 1936  827.071(4)           2nd   Possess with intent to promote any photographic material, motion picture, etc., which includes sexual conduct by a child.
 1937  827.071(5)           3rd   Possess, control, or intentionally view any photographic material, motion picture, etc., which includes sexual conduct by a child.
 1938  839.13(2)(b)         2nd   Falsifying records of an individual in the care and custody of a state agency involving great bodily harm or death.
 1939  843.01               3rd   Resist officer with violence to person; resist arrest with violence.
 1940  847.0135(5)(b)       2nd   Lewd or lascivious exhibition using computer; offender 18 years or older.
 1941  847.0137 (2) & (3)   3rd   Transmission of pornography by electronic device or equipment.
 1942  847.0138 (2) & (3)   3rd   Transmission of material harmful to minors to a minor by electronic device or equipment.
 1943  874.05(1)(b)         2nd   Encouraging or recruiting another to join a criminal gang; second or subsequent offense.
 1944  874.05(2)(a)         2nd   Encouraging or recruiting person under 13 years of age to join a criminal gang.
 1945  893.13(1)(a)1.       2nd   Sell, manufacture, or deliver cocaine (or other s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4. drugs).
 1946  893.13(1)(c)2.       2nd   Sell, manufacture, or deliver cannabis (or other s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) drugs) within 1,000 feet of a child care facility, school, or state, county, or municipal park or publicly owned recreational facility or community center.
 1947  893.13(1)(d)1.       1st   Sell, manufacture, or deliver cocaine (or other s. 893.03(1)(a), (1)(b), (1)(d), (2)(a), (2)(b), or (2)(c)4. drugs) within 1,000 feet of university.
 1948  893.13(1)(e)2.       2nd   Sell, manufacture, or deliver cannabis or other drug prohibited under s. 893.03(1)(c), (2)(c)1., (2)(c)2., (2)(c)3., (2)(c)5., (2)(c)6., (2)(c)7., (2)(c)8., (2)(c)9., (3), or (4) within 1,000 feet of property used for religious services or a specified business site.
 1949  893.13(1)(f)1.       1st   Sell, manufacture, or deliver cocaine (or other s. 893.03(1)(a), (1)(b), (1)(d), or (2)(a), (2)(b), or (2)(c)4. drugs) within 1,000 feet of public housing facility.
 1950  893.13(4)(b)         2nd   Use or hire of minor; deliver to minor other controlled substance.
 1951  893.1351(1)          3rd   Ownership, lease, or rental for trafficking in or manufacturing of controlled substance.
 1952         Section 22. This act shall take effect October 1, 2017.